Related Experiment Videos
Thromboxane receptor blockade with SQ 30,741 improves post-ischemic myocardial function in anesthetized dogs
1Department of Pharmacology, Squibb Institute for Medical Research, Princeton, New Jersey 08543-4000.
Summary
The thromboxane A2 receptor antagonist SQ 30,741 improved cardiac function recovery after ischemia in dogs. This suggests thromboxane antagonists may help treat myocardial stunning.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial stunning is a post-ischemic cardiac dysfunction.
- Thromboxane A2 is implicated in the pathogenesis of myocardial stunning.
Purpose of the Study:
- To investigate the efficacy of thromboxane A2 receptor antagonist SQ 30,741 in improving cardiac function after ischemia.
Main Methods:
- Anesthetized dogs underwent 15-minute coronary occlusion and 5-hour reperfusion.
- Saline or SQ 30,741 was infused during occlusion and reperfusion.
- Subendocardial ultrasonic crystals assessed regional cardiac function.
Main Results:
- SQ 30,741 significantly improved ventricular segmental shortening during reperfusion.
- At 5 hours post-reperfusion, segmental shortening was 44% of baseline in the SQ 30,741 group versus 3% in the saline group.
- No differences in collateral or reperfusion blood flow were observed between groups.
Conclusions:
- Thromboxane receptor activation contributes to myocardial stunning.
- Thromboxane antagonists like SQ 30,741 may be beneficial in mitigating post-ischemic cardiac dysfunction.